Catalog No.
DHF90701
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-Kappa
Clonality
Monoclonal
Target
Neurotrophic tyrosine kinase, receptor-related 1, Inactive tyrosine-protein kinase transmembrane receptor ROR1, NTRKR1, ROR1
Concentration
4.69mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q01973
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
cirmtuzumab, CAS: 2485779-13-1
Clone ID
Zilovertamab
Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia., PMID:40295829
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population., PMID:39438409
Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein., PMID:39062146
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer., PMID:38481291
A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation., PMID:38434151
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer., PMID:38408999
The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma., PMID:37672954
Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial., PMID:37029329
Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway., PMID:36944183
Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter's Syndrome., PMID:36551520
Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies., PMID:35892876
ROR1: an orphan becomes apparent., PMID:35580162
New Directions for Mantle Cell Lymphoma in 2022., PMID:35561299
The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells., PMID:35456672
High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia., PMID:35418613
Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia., PMID:35406490
ROR1 for Lymphoid Cancers., PMID:38319244
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers., PMID:38319241
Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia., PMID:34686499
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study., PMID:34618601
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation., PMID:33689703
Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism., PMID:33097837
ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia., PMID:32579248
Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials., PMID:32407139
The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia., PMID:32090643
NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia., PMID:31992855
Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis., PMID:31667337
MicroRNA dysregulation and multi-targeted therapy for cancer treatment., PMID:31640928
Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia., PMID:31409670
Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody., PMID:30622177
Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells., PMID:30568170
Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma., PMID:29872501
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia., PMID:29859176
Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia., PMID:29678828
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)., PMID:29048660
MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia., PMID:28923920
Molecular genetics and targeted therapy of WNT-related human diseases (Review)., PMID:28731148
Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells., PMID:28465529
Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells., PMID:28465528
Targeting ROR1 identifies new treatment strategies in hematological cancers., PMID:28408486
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib., PMID:27904138
Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation., PMID:26690702
Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1., PMID:26297272
For research use only. Not for human or drug use.
